Nuveen Asset Management, LLC Amylyx Pharmaceuticals, Inc. Transaction History

Nuveen Asset Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$2.71 - $19.57 $2.39 Million - $17.3 Million	-883,684 Reduced 86.5%	137,973 $391,000
Q4 2023 Feb 14, 2024	BUY	$12.07 - $18.46 $257,163 - $393,308	21,306 Added 2.13%	1,021,657 $15 Million
Q3 2023 Nov 14, 2023	BUY	$18.08 - $23.45 $8.09 Million - $10.5 Million	447,277 Added 80.87%	1,000,351 $18.3 Million
Q2 2023 Aug 14, 2023	SELL	$20.98 - $31.42 $1.23 Million - $1.85 Million	-58,858 Reduced 9.62%	553,074 $11.9 Million
Q1 2023 May 15, 2023	BUY	$27.71 - $40.93 $439,979 - $649,886	15,878 Added 2.66%	611,932 $18 Million
Q4 2022 Feb 14, 2023	BUY	$29.75 - $39.26 $7.12 Million - $9.4 Million	239,367 Added 67.11%	596,054 $22 Million
Q3 2022 Nov 14, 2022	BUY	$17.15 - $30.92 $5.44 Million - $9.81 Million	317,200 Added 803.3%	356,687 $6.39 Million
Q2 2022 Aug 15, 2022	BUY	$6.85 - $19.93 $179,860 - $523,302	26,257 Added 198.47%	39,487 $761,000
Q1 2022 May 16, 2022	BUY	$12.85 - $32.9 $170,005 - $435,267	13,230 New	13,230 $170,000

127

44.4M

235K

530K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $310M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nuveen Asset Management, LLC with notifications on news.